431 related articles for article (PubMed ID: 29525278)
1. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
[TBL] [Abstract][Full Text] [Related]
2. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.
van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA
Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge.
Lulla V; Losada A; Lecollinet S; Kerviel A; Lilin T; Sailleau C; Beck C; Zientara S; Roy P
Vaccine; 2017 Jul; 35(33):4262-4269. PubMed ID: 28625521
[TBL] [Abstract][Full Text] [Related]
7. African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014.
Weyer CT; Grewar JD; Burger P; Rossouw E; Lourens C; Joone C; le Grange M; Coetzee P; Venter E; Martin DP; MacLachlan NJ; Guthrie AJ
Emerg Infect Dis; 2016 Dec; 22(12):2087-2096. PubMed ID: 27442883
[TBL] [Abstract][Full Text] [Related]
8. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
9. The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.
van Rijn PA; Maris-Veldhuis MA; van Gennip RGP
Viruses; 2021 May; 13(5):. PubMed ID: 34067226
[TBL] [Abstract][Full Text] [Related]
10. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine.
Weyer CT; Grewar JD; Burger P; Joone C; Lourens C; MacLachlan NJ; Guthrie AJ
Vaccine; 2017 Apr; 35(18):2504-2510. PubMed ID: 28341113
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
[TBL] [Abstract][Full Text] [Related]
13. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
[TBL] [Abstract][Full Text] [Related]
14. Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.
van Gennip RGP; van de Water SGP; Potgieter CA; van Rijn PA
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903804
[TBL] [Abstract][Full Text] [Related]
15. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.
Calvo-Pinilla E; Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
Curr Opin Virol; 2020 Oct; 44():49-56. PubMed ID: 32659516
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals.
von Teichman BF; Smit TK
Vaccine; 2008 Sep; 26(39):5014-21. PubMed ID: 18682269
[TBL] [Abstract][Full Text] [Related]
17. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
[TBL] [Abstract][Full Text] [Related]
18. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
Rutkowska DA; Mokoena NB; Tsekoa TL; Dibakwane VS; O'Kennedy MM
BMC Vet Res; 2019 Dec; 15(1):432. PubMed ID: 31796116
[TBL] [Abstract][Full Text] [Related]
19. Development of a mouse model system, coding assignments and identification of the genome segments controlling virulence of African horse sickness virus serotypes 3 and 8.
O'Hara RS; Meyer AJ; Burroughs JN; Pullen L; Martin LA; Mertens PP
Arch Virol Suppl; 1998; 14():259-79. PubMed ID: 9785512
[TBL] [Abstract][Full Text] [Related]
20. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
